| 1. | Altenergy | |
| 2. | TradeChem | |
| 3. | ChemCritique | |
| 4. | E3attendee | |
| 5. | lopopclvp1nv3poo |
Top Board Researchers
These are the top researchers based on quality of posts as voted by board members. Typically they know their stuff and are a great
way to catch up on what the company is all about.
HOW DO I BECOME ONE?
Just do great research! As other members approve of your posts, you earn points that move you up the ranks.| 1. | Altenergy 09/12/2017 Bank of America Merrill Lynch Global Healthcare Conference |
| 2. | E3attendee 02/01/2018 Misses EPS estimates by $0.14. Slightly misses on revenues. |
| 3. | corrosivedeath 01/30/2018 Confirms the EMA's CHMP adopted a positive opinion recommending a label variation for KYPROLIS to include u… |
| 4. | ChemCritique 04/03/2018 European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma |
| 5. | TradeChem 09/12/2017 @Altenergy Got you! One sec. TradeChem Clicking thumbs up, bookmarking, and following me are all ways of saying, "Hey, thanks!" and is much appreciated! |
| 6. | ChemCritique 10/25/2017 Revenue decline but tops expectations |
| 7. | corrosivedeath 03/26/2018 Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes |
| 8. | ChemCritique 09/14/2017 FDA Approved! |
| 9. | corrosivedeath 02/27/2018 Amgen To Present New Data From Repatha® (evolocumab) Clinical Trials At ACC.18 |
| 10. | lopopclvp1nv3poo 02/02/2018 BMO Capital |
NEW since the last time you visited this board.
Currently a TOP 10 POST for this board.
Currently a TOP 5 RESEARCHER for this board.
Specific post has replies to it.
A Researcher you are currently FOLLOWING
Other Researchers rate this post HIGH
Other Researchers rate this post LOW
Amgen Inc.
- AMGN
- Public Stock Message Board
Filtering by:
-
To use your chart in a post, click the
icon above the chart. From there you can get the chart link or download the image.